Swiss meals and beverage giant Nestle (OTCPK:NSRGY) is having to pay a lot more than $2 billion for Aimmune Therapeutics, Inc. (AIMT) to bag the California-centered firm’s drug Palforzia, a peanut allergy treatment that was accepted by the Foods and Drug Administration earlier this yr.
Nestle by now owned a lot more than twenty five% of Aimmune. The all-hard cash deal values the organization at $2.6 billion. At $34.fifty for each share, the price tag amounts to a 174% top quality on Aimmune’s closing price tag as of Friday, as Nestlé explained in the information launch. The obtain is expected